ArticleiScience2024

An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.

Xuan Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.